News/ News/ Oncology/ Top stories China’s BeiGene delays US filing for rival to Imbruvica Phil Taylor BeiGene, BTK inhibitor, Imbruvica, zanubrutinib 0 Comment BeiGene’s plans for an early approval for BTK inhibitor zanubrutinib in the US and to start challenging Janssen/AbbVie’s Share X China’s BeiGene delays US filing for rival to Imbruvica https://pharmaphorum.com/news/chinas-beigene-delays-us-filing-for-rival-to-imbruvica/
